Key result
Novel compound 3q demonstrates oral antithrombotic efficacy without significantly increasing bleeding time in preclinical models.
Answers are grounded in this paper and cite their sources.
The coagulation enzyme factor Xa (FXa) has been recognized as a promising target for the development of new antithrombotic agents. We previously found compound 1 to be an orally bioavailable FXa inhibitor in fasted monkeys; however, 1 showed poor bioavailability in rats and fed monkeys. To work out the pharmacokinetic problems, we focused our synthetic efforts on the chemical conversion of the 4-(imidazo[1,2- a]pyridin-5-yl)piperazine moiety of 1 to imidazolylpiperidine derivatives (fused and nonfused), which resulted in the discovery of the weakly basic imidazo[1,5- c]imidazol-3-one 3q as a potent and selective FXa inhibitor. Compound 3q showed favorable oral bioavailability in rats and monkeys under both fasted and fed conditions and antithrombotic efficacy in a rat model of venous thrombosis after oral administration, without a significant increase in bleeding time (unlike warfarin). On the basis of these promising properties, compound 3q was selected for further evaluation.
No takes yet. Share an insight, caveat, or question.
Imaeda et al. (2008) studied Venous thrombosis (preclinical animal models). Imidazo[1,5-c]imidazol-3-one 3q (Factor Xa inhibitor) vs. Warfarin / Compound 1 was evaluated on Oral bioavailability, antithrombotic efficacy, and bleeding time. Compound 3q showed favorable oral bioavailability in rats and monkeys and antithrombotic efficacy in rat venous thrombosis without significantly increasing bleeding time.
Synapse has enriched 10 related papers. Consider them for comparative context: